AdaptHealth (AHCO) has just posted its latest results with Q4 2025 revenue of US$846.3 million and a basic EPS loss of US$0.74, setting the tone for how investors will read the Q1 2026 update. The company has seen quarterly revenue move from US$856.6 million in Q4 2024 to US$846.3 million in Q4 2025, while EPS shifted from US$0.34 to a loss of US$0.74 over the same period. This puts the focus squarely on earnings quality. With the stock trading at US$11.75, investors may pay close attention to how margins stabilise and whether the latest numbers indicate any change in the company’s profit profile.

See our full analysis for AdaptHealth.

With the headline figures on the table, the next step is to set these results against the prevailing narratives about AdaptHealth's growth potential, profitability path, and risk profile to see which views hold up and which start to look out of date.

Trailing 12 months still in loss territory

• On a trailing 12 month basis to Q4 2025, AdaptHealth generated about US$3.2b of revenue and a loss of US$70.8 million, with basic EPS at a loss of US$0.52, so the business is currently not profitable over the year as a whole.
• Consensus narrative highlights a path back to earnings of US$157.7 million by 2028 with profit margins rising from 2.3% to 3.9%. This sits against the recent trailing loss, which means:
  • The long term view expects earnings growth of 25.57% per year and a return to profitability within three years, while the latest 12 month figures still show losses. The turnaround thesis therefore leans heavily on future improvement rather than what is already in the numbers.
  • Revenue is forecast to grow at 5.9% a year compared with a cited 11.2% for the broader US market, so the balanced view depends more on margin improvement than on AdaptHealth suddenly matching market level revenue growth.

EPS swings highlight profit volatility

• Quarterly basic EPS moved from a profit of US$0.17 in Q3 2025 to a loss of US$0.74 in Q4 2025, with full year 2025 EPS ranging between a loss of US$0.05 and a profit of US$0.17, which points to quite a wide range of outcomes from quarter to quarter.
• Bears argue that high fixed costs and reimbursement pressure could cap long term earnings even with solid revenue, and the EPS pattern gives that cautious view some support because:
  • Net income swung from a profit of US$22.5 million in Q3 2025 to a loss of US$100.1 million in Q4 2025 on roughly similar revenue levels, which suggests profit is sensitive to cost movements and mix effects rather than just sales volume.
  • Losses have grown at about 19.3% a year over the past five years on the data provided, so even though analysts model future margin gains, recent history still reflects pressure on the income statement that bears focus on.

On these numbers, skeptics point to the sharp EPS swings as a reason to question how quickly profit can stabilise, especially with reimbursement and cost risks still in play for the next few years. 🐻 AdaptHealth Bear Case

Valuation gap versus DCF fair value

• The stock trades at US$11.75 with a P/S of 0.5x, compared with a DCF fair value of US$29.41 and a peer P/S average of 0.3x, so the shares sit below that DCF estimate while also being priced higher than peers on sales.
• Bulls point to forecasts of earnings growth of 25.57% a year and a move to profitability within three years, and the current valuation gap feeds that optimistic angle because:
  • The DCF fair value of US$29.41 is well above the current price of US$11.75, yet the P/S of 0.5x is still lower than the 1.2x average in the wider US Healthcare industry. Bulls see this as room for re rating if the profit story plays out.
  • Analysts also reference an overall price target of US$13.44, which is closer to the current price than the DCF fair value. The key question for bullish investors is whether future execution can justify a move toward the higher DCF based figure rather than just the nearer term target.

If you want to see how those growth and margin expectations stack up against the optimistic case in more detail, the full bull thesis sets out the assumptions behind that stronger upside view. 🐂 AdaptHealth Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AdaptHealth on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of bullish and cautious views leaves you on the fence, it may be helpful to look at the numbers directly and compare each narrative with your own expectations. To understand what the optimism is based on, you can start with the company’s key upside drivers in the 2 key rewards.

See What Else Is Out There

Between the trailing 12 month loss, sharp EPS swings, and sensitivity to costs, AdaptHealth currently shows earnings volatility that some investors may find uncomfortable.

If you want a smoother ride than that kind of profit swing, it could be worth checking out 72 resilient stocks with low risk scores as a starting point for alternatives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.